Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

In vitro glucuronidation of 7-hydroxycoumarin derivatives in intestine and liver microsomes of Beagle dogs.

Juvonen RO, Heikkinen AT, Kärkkäinen O, Jehangir R, Huuskonen J, Troberg J, Raunio H, Pentikäinen OT, Finel M.

Eur J Pharm Sci. 2020 Jan 1;141:105118. doi: 10.1016/j.ejps.2019.105118. Epub 2019 Oct 25.

PMID:
31669387
2.

Metabolism of Scoparone in Experimental Animals and Humans.

Juvonen RO, Novák F, Emmanouilidou E, Auriola S, Timonen J, Heikkinen AT, Küblbeck J, Finel M, Raunio H.

Planta Med. 2019 Apr;85(6):453-464. doi: 10.1055/a-0835-2301. Epub 2019 Feb 8.

PMID:
30736072
3.

Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes.

Juvonen RO, Ahinko M, Huuskonen J, Raunio H, Pentikäinen OT.

Xenobiotica. 2019 Sep;49(9):1015-1024. doi: 10.1080/00498254.2018.1530399. Epub 2018 Nov 29.

PMID:
30272491
4.

New glutathione conjugate of pyrrolizidine alkaloids produced by human cytosolic enzyme-dependent reactions in vitro.

Muluneh F, Häkkinen MR, El-Dairi R, Pasanen M, Juvonen RO.

Rapid Commun Mass Spectrom. 2018 Aug 30;32(16):1344-1352. doi: 10.1002/rcm.8173.

PMID:
29788543
5.

Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives.

Niinivehmas S, Postila PA, Rauhamäki S, Manivannan E, Kortet S, Ahinko M, Huuskonen P, Nyberg N, Koskimies P, Lätti S, Multamäki E, Juvonen RO, Raunio H, Pasanen M, Huuskonen J, Pentikäinen OT.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):743-754. doi: 10.1080/14756366.2018.1452919.

6.

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.

Rauhamäki S, Postila PA, Niinivehmas S, Kortet S, Schildt E, Pasanen M, Manivannan E, Ahinko M, Koskimies P, Nyberg N, Huuskonen P, Multamäki E, Pasanen M, Juvonen RO, Raunio H, Huuskonen J, Pentikäinen OT.

Front Chem. 2018 Mar 2;6:41. doi: 10.3389/fchem.2018.00041. eCollection 2018.

7.

Molecular Docking-Based Design and Development of a Highly Selective Probe Substrate for UDP-glucuronosyltransferase 1A10.

Juvonen RO, Rauhamäki S, Kortet S, Niinivehmas S, Troberg J, Petsalo A, Huuskonen J, Raunio H, Finel M, Pentikäinen OT.

Mol Pharm. 2018 Mar 5;15(3):923-933. doi: 10.1021/acs.molpharmaceut.7b00871. Epub 2018 Feb 15.

8.

Comparison of In Vitro Hepatic Scoparone 7-O-Demethylation between Humans and Experimental Animals.

Fayyaz A, Makwinja S, Auriola S, Raunio H, Juvonen RO.

Planta Med. 2018 Mar;84(5):320-328. doi: 10.1055/s-0043-119886. Epub 2017 Sep 26.

PMID:
28950382
9.

Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes.

Raunio H, Juvonen RO, Poso A, Lahtela-Kakkonen M, Rahnasto-Rilla M.

Drug Metab Lett. 2016;10(1):56-64.

PMID:
26648056
10.

Species-Specific Differences in the in Vitro Metabolism of Lasiocarpine.

Fashe MM, Juvonen RO, Petsalo A, Räsänen J, Pasanen M.

Chem Res Toxicol. 2015 Oct 19;28(10):2034-44. doi: 10.1021/acs.chemrestox.5b00253. Epub 2015 Oct 2.

PMID:
26395423
11.

Comparison of trapping profiles between d-peptides and glutathione in the identification of reactive metabolites.

Laine JE, Häkkinen MR, Auriola S, Juvonen RO, Pasanen M.

Toxicol Rep. 2015 Jul 9;2:1024-1032. doi: 10.1016/j.toxrep.2015.07.002. eCollection 2015.

12.

Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.

Raunio H, Kuusisto M, Juvonen RO, Pentikäinen OT.

Front Pharmacol. 2015 Jun 12;6:123. doi: 10.3389/fphar.2015.00123. eCollection 2015. Review.

13.

Inhibitory effects and oxidation of 6-methylcoumarin, 7-methylcoumarin and 7-formylcoumarin via human CYP2A6 and its mouse and pig orthologous enzymes.

Juvonen RO, Kuusisto M, Fohrgrup C, Pitkänen MH, Nevalainen TJ, Auriola S, Raunio H, Pasanen M, Pentikäinen OT.

Xenobiotica. 2016;46(1):14-24. doi: 10.3109/00498254.2015.1048327. Epub 2015 Jun 11.

PMID:
26068522
14.

In silico prediction of the site of oxidation by cytochrome P450 3A4 that leads to the formation of the toxic metabolites of pyrrolizidine alkaloids.

Fashe MM, Juvonen RO, Petsalo A, Vepsäläinen J, Pasanen M, Rahnasto-Rilla M.

Chem Res Toxicol. 2015 Apr 20;28(4):702-10. doi: 10.1021/tx500478q. Epub 2015 Feb 17.

PMID:
25651456
15.

Rational design of novel CYP2A6 inhibitors.

Tani N, Juvonen RO, Raunio H, Fashe M, Leppänen J, Zhao B, Tyndale RF, Rahnasto-Rilla M.

Bioorg Med Chem. 2014 Dec 1;22(23):6655-6664. doi: 10.1016/j.bmc.2014.10.001. Epub 2014 Oct 13.

PMID:
25458499
16.

Identification of a new reactive metabolite of pyrrolizidine alkaloid retrorsine: (3H-pyrrolizin-7-yl)methanol.

Fashe MM, Juvonen RO, Petsalo A, Rahnasto-Rilla M, Auriola S, Soininen P, Vepsäläinen J, Pasanen M.

Chem Res Toxicol. 2014 Nov 17;27(11):1950-7. doi: 10.1021/tx5002964. Epub 2014 Oct 21.

PMID:
25295702
17.

Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.

Poutiainen PK, Huhtala T, Jääskeläinen T, Petsalo A, Küblbeck J, Kaikkonen S, Palvimo JJ, Raunio H, Närvänen A, Peräkylä M, Juvonen RO, Honkakoski P, Laatikainen R, Pulkkinen JT.

Mol Cell Endocrinol. 2014 Apr 25;387(1-2):8-18. doi: 10.1016/j.mce.2014.02.008. Epub 2014 Feb 22.

PMID:
24565895
18.

A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes.

Rahikainen T, Häkkinen MR, Finel M, Pasanen M, Juvonen RO.

Xenobiotica. 2013 Oct;43(10):853-61. doi: 10.3109/00498254.2013.783724. Epub 2013 Apr 3.

PMID:
23551063
19.

Interactions of inhibitor molecules with the human CYP2E1 enzyme active site.

Martikainen LE, Rahnasto-Rilla M, Neshybova S, Lahtela-Kakkonen M, Raunio H, Juvonen RO.

Eur J Pharm Sci. 2012 Dec 18;47(5):996-1005. doi: 10.1016/j.ejps.2012.09.018. Epub 2012 Oct 13.

PMID:
23069620
20.

Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs.

Huttunen KM, Tani N, Juvonen RO, Raunio H, Rautio J.

Mol Pharm. 2013 Feb 4;10(2):532-7. doi: 10.1021/mp300330v. Epub 2012 Aug 31.

PMID:
22937971
21.

ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells.

Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR.

Int J Pharm. 2012 Nov 1;437(1-2):29-41. doi: 10.1016/j.ijpharm.2012.07.062. Epub 2012 Aug 4.

PMID:
22890189
22.

Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD, Vasiliou V.

Pharmacol Rev. 2012 Jul;64(3):520-39. doi: 10.1124/pr.111.005538. Epub 2012 Apr 27. Review.

23.

Metabolism of bilirubin by human cytochrome P450 2A6.

Abu-Bakar A, Arthur DM, Wikman AS, Rahnasto M, Juvonen RO, Vepsäläinen J, Raunio H, Ng JC, Lang MA.

Toxicol Appl Pharmacol. 2012 May 15;261(1):50-8. doi: 10.1016/j.taap.2012.03.010. Epub 2012 Mar 24.

PMID:
22465937
24.

Apoptosis-induced anticancer effect of transferrin-conjugated solid lipid nanoparticles of curcumin.

Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR.

Cancer Nanotechnol. 2012;3(1-6):65-81. Epub 2012 Nov 13.

25.

Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.

Tani N, Rahnasto-Rilla M, Wittekindt C, Salminen KA, Ritvanen A, Ollakka R, Koskiranta J, Raunio H, Juvonen RO.

Eur J Med Chem. 2012 Jan;47(1):270-7. doi: 10.1016/j.ejmech.2011.10.053. Epub 2011 Nov 6.

PMID:
22100140
26.

Identification of novel CYP2A6 inhibitors by virtual screening.

Rahnasto MK, Raunio HA, Wittekindt C, Salminen KA, Leppänen J, Juvonen RO, Poso A, Lahtela-Kakkonen MK.

Bioorg Med Chem. 2011 Dec 1;19(23):7186-93. doi: 10.1016/j.bmc.2011.09.054. Epub 2011 Oct 4.

PMID:
22019468
27.

2'-Deoxyguanosine as a surrogate trapping agent for DNA reactive drug metabolites.

Häkkinen MR, Laine JE, Juvonen RO, Auriola S, Häyrinen J, Pasanen M.

Toxicol Lett. 2011 Nov 10;207(1):34-41. doi: 10.1016/j.toxlet.2011.08.020. Epub 2011 Sep 2.

PMID:
21907773
28.

Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics.

Salminen KA, Leppänen J, Venäläinen JI, Pasanen M, Auriola S, Juvonen RO, Raunio H.

Drug Metab Dispos. 2011 Mar;39(3):412-8. doi: 10.1124/dmd.110.036376. Epub 2010 Dec 9.

PMID:
21148250
29.

D-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry.

Laine JE, Auriola S, Pasanen M, Juvonen RO.

Toxicol In Vitro. 2011 Feb;25(1):411-25. doi: 10.1016/j.tiv.2010.11.002. Epub 2010 Nov 12.

PMID:
21075197
30.

Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.

Salminen KA, Meyer A, Jerabkova L, Korhonen LE, Rahnasto M, Juvonen RO, Imming P, Raunio H.

Phytomedicine. 2011 Apr 15;18(6):533-8. doi: 10.1016/j.phymed.2010.08.012. Epub 2010 Sep 20.

PMID:
20851588
31.

Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis.

Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR.

Int J Pharm. 2010 Oct 15;398(1-2):190-203. doi: 10.1016/j.ijpharm.2010.07.021. Epub 2010 Jul 22.

PMID:
20655375
32.
33.

Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes.

Laine JE, Auriola S, Pasanen M, Juvonen RO.

Xenobiotica. 2009 Jan;39(1):11-21. doi: 10.1080/00498250802512830 .

PMID:
19219744
34.

Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo.

Raunio H, Pokela N, Puhakainen K, Rahnasto M, Mauriala T, Auriola S, Juvonen RO.

Xenobiotica. 2008 Jan;38(1):34-47.

PMID:
18098062
35.

Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.

Rahnasto M, Wittekindt C, Juvonen RO, Turpeinen M, Petsalo A, Pelkonen O, Poso A, Stahl G, Höltje HD, Raunio H.

Pharmacogenomics J. 2008 Oct;8(5):328-38. Epub 2007 Oct 9.

PMID:
17923852
36.

Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.

Myllymäki MJ, Saario SM, Kataja AO, Castillo-Melendez JA, Nevalainen T, Juvonen RO, Järvinen T, Koskinen AM.

J Med Chem. 2007 Aug 23;50(17):4236-42. Epub 2007 Aug 1. Erratum in: J Med Chem. 2007 Nov 15;50(23):5868.

PMID:
17665899
37.

Lactobacillus rhamnosus strain GG reduces aflatoxin B1 transport, metabolism, and toxicity in Caco-2 Cells.

Gratz S, Wu QK, El-Nezami H, Juvonen RO, Mykkänen H, Turner PC.

Appl Environ Microbiol. 2007 Jun;73(12):3958-64. Epub 2007 Apr 20.

38.

Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.

Huttunen KM, Mähönen N, Leppänen J, Vepsäläinen J, Juvonen RO, Raunio H, Kumpulainen H, Järvinen T, Rautio J.

Pharm Res. 2007 Apr;24(4):679-87. Epub 2007 Feb 15.

PMID:
17372695
39.

New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis.

Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso A, Pelkonen O, Raunio H, Juvonen RO.

Br J Pharmacol. 2007 Apr;150(7):932-42. Epub 2007 Feb 26.

40.

Lactobacillus rhamnosus strain GG modulates intestinal absorption, fecal excretion, and toxicity of aflatoxin B(1) in rats.

Gratz S, Täubel M, Juvonen RO, Viluksela M, Turner PC, Mykkänen H, El-Nezami H.

Appl Environ Microbiol. 2006 Nov;72(11):7398-400. Epub 2006 Sep 15.

41.

Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.

Saario SM, Poso A, Juvonen RO, Järvinen T, Salo-Ahen OM.

J Med Chem. 2006 Jul 27;49(15):4650-6.

PMID:
16854070
42.

Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China.

El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling W, Salminen EK, Juvonen RO, Salminen SJ, Poussa T, Mykkänen HM.

Am J Clin Nutr. 2006 May;83(5):1199-203.

PMID:
16685066
43.

Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.

Kumpulainen H, Mähönen N, Laitinen ML, Jaurakkajärvi M, Raunio H, Juvonen RO, Vepsäläinen J, Järvinen T, Rautio J.

J Med Chem. 2006 Feb 9;49(3):1207-11.

PMID:
16451086
44.

Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.

Korhonen LE, Rahnasto M, Mähönen NJ, Wittekindt C, Poso A, Juvonen RO, Raunio H.

J Med Chem. 2005 Jun 2;48(11):3808-15.

PMID:
15916432
45.

Fecal and urinary excretion of aflatoxin B1 metabolites (AFQ1, AFM1 and AFB-N7-guanine) in young Chinese males.

Mykkänen H, Zhu H, Salminen E, Juvonen RO, Ling W, Ma J, Polychronaki N, Kemiläinen H, Mykkänen O, Salminen S, El-Nezami H.

Int J Cancer. 2005 Jul 20;115(6):879-84.

46.

Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.

Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO.

J Med Chem. 2005 Jan 27;48(2):440-9.

PMID:
15658857
47.

Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.

Forsberg MM, Juvonen RO, Helisalmi P, Leppänen J, Gogos JA, Karayiorgou M, Männistö PT.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Oct;370(4):279-89. Epub 2004 Sep 17.

PMID:
15378229
48.

Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.

Venäläinen JI, Juvonen RO, Garcia-Horsman JA, Wallén EA, Christiaans JA, Jarho EM, Gynther J, Männistö PT.

Biochem J. 2004 Sep 15;382(Pt 3):1003-8.

49.

Evolutionary relationships of the prolyl oligopeptidase family enzymes.

Venäläinen JI, Juvonen RO, Männistö PT.

Eur J Biochem. 2004 Jul;271(13):2705-15.

50.

Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes.

Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO.

Toxicol In Vitro. 2003 Aug;17(4):449-55.

PMID:
12849728

Supplemental Content

Loading ...
Support Center